Program:
*Clinical Trial Design with Engineered Antibodies
*MAb Optimization for Therapy
*PRIMATIZED Antibodies
*Minimizing Host Immune Response to Therapeutic Antibodies
*Genetic Manipulations of Antibody CDRs
*Toxicology Studies
*Cross Reactivity Studies
*Clinical Trials with Single Chain Fv Antibodies
*Recombinant Antibodies from Combinatorial Libraries
Registration :
For further information: tel: 508-481-6400, fax: 508-481-4473
online: www.ibcusa.com/conf/therapeutics
Deadline for Abstracts: Poster Abstracts: May 8, 1997
Email for Requests and Registration: emassa@ibcusa.com